Baseimmune

baseimmune.

designing vaccines with plasticity

About Us

Baseimmune is a biotech startup founded to create the next generation of vaccines. Our unique platform is based on innovative and powerful technology that generates antigens using a level of informatics depth not previously seen. With our method, we are able to make sense of the ever growing amount of genomic and epidemiological data that is then incorporated in the design of universal vaccines.

Using this approach we are able to tackle emerging and challenging pathogens that had been failed by traditional approaches. Importantly, we are able to ensure our vaccines remain effective even when the pathogen mutates.

As a discovery stage biotech, we develop broad-spectrum vaccines against highly variable pathogens.

Technology

Predict the future.

Pathogens are evolving constantly to adapt and ensure their survival. As a result they are a constantly moving target for vaccines. Some vaccines may work for a short period, whilsts others may never be able to keep up with a pathogens variation. Baseimmune uses deep learning to predict the direction that a pathogen will take to create vaccines that are many steps ahead and future proof. Introducing Baseimmune vaccines with plasticity.

To create vaccines with plasticity.

Our technologies are based on a data-driven platform for the analysis of pathogen genomics, proteomics, epidemiology, evolution and clinical data for the generation of vaccine antigens effective against current and future unknown strains and variants.

With talented vaccine experts, scientists, bioinformaticians and software engineer in the field, Baseimmune is committed to translating ‘OMICs’ big-data into real-world solutions. By collaborating with leading institutions and companies and an expert panel of scientific advisors, we hope to develop vaccines and reduce the burden of infectious diseases in human and animal health.

Joshua Blight

Ariane C. Gomes

Phillip Kemlo

Co-founder, CEO

Co-founder, CSO

Co-founder, CTO

Head of Operations

Lab Manager

Senior Scientist

Ana Moldoveanu

Research Scientist

Senior Bioinformatician

Danny

Goovaerts

Michael

Watson

Prof. Jake

Baum

Veterinary Commercial Advisor

Human Commercial Advisor

Scientific Advisor

Scientific Advisory Board

Pipeline

The Baseimmune pipeline currently focuses on major challenges in infectious diseases. We are building a unique pipeline to address veterinary and human threats worldwide.

DESIGN

PRECLINICAL

PHASE I

BSIvet-001 vaccine

BSIhum-002 vaccine

BSIhum-003 vaccine

Universal African Swine Fever

Universal Coronavirus

Universal Malaria

Our bespoke antigen discovery platform allied with superior vaccine delivery systems, allow us to fast track the discovery phase of vaccines and move faster to preclinical pipeline.

News

Baseimmune raises seed investment - Oct 21

Baseimmune $4.8M to continue development of future-proof vaccines

Read more ➤

Q&A - Who are we?

meet the Baseimmune team and find out what we do

Read more ➤

Co-development of a malaria vaccine

Baseimmune is combining forces with Imperial College to develop a radically new malaria vaccine

Read more ➤

Baseimmune raises pre-seed investment - Apr 21

Baseimmune team raises funds to create future-proof vaccines

Read more ➤

Baseimmune selected for the KQLabs accelerator

Baseimmune joins cohort 2 of the KQLabs accelerator program held at the Crick Institute

Read more ➤

> more

Career Opportunities

Join the team to harness the power of our computational platform to design and create variant-proof vaccines. Check our careers page for available positions.

See Opportunities

Working with world-class

research institutes and industry